Full text is available at the source.
Abstract
Long-acting GLP-1 receptor agonists show greater reductions in fasting plasma glucose compared to shorter-acting formulations.
- GLP-1 receptor agonists improve glucose metabolism by enhancing insulin secretion and reducing glucagon release.
- Differences in drug characteristics lead to varying effects on fasting and post-prandial glucose levels.
- Liraglutide once daily and exenatide once weekly significantly lower fasting plasma glucose but have less impact on post-prandial glucose spikes.
- Shorter-acting prandial GLP-1 receptor agonists like exenatide twice daily effectively manage post-prandial glucose through delayed gastric emptying.
- Lixisenatide once daily strongly suppresses post-prandial glucagon secretion, enhancing its glucose-lowering effects.
- Prandial GLP-1 receptor agonists may be best utilized in combination with basal insulin for optimal management of type 2 diabetes mellitus.
Simplified